Dermatomyositis Clinical Trials
Here are the 2 most popular medical studies for dermatomyositis
DM Clinical Trials
View 8 DM medical studies.
Immunoglobulin G for Dermatomyositis
This trial is testing if a new drug, IgPro20, is effective in treating dermatomyositis (DM) in adults. The primary objective is to compare IgPro20 to placebo in terms of Total Improvement Score (TIS) assessments.
Frequently Asked Questions
Introduction to dermatomyositis
What are the top hospitals conducting dermatomyositis research?
When it comes to advancing research and treatment options for dermatomyositis, several hospitals across the United States are making significant strides. In Saint Louis, Washington University School of Medicine leads with three active clinical trials focused on this rare inflammatory disease that affects both the skin and muscles. Since their first recorded trial in 2017, they have committed to understanding and improving the lives of those living with dermatomyositis. Meanwhile, in Fairway, Kansas, the KU Clinical Research Center - Clinical and Translational Science Unit (CTSU) is actively engaged in two ongoing dermatomyositis trials. With a history of three previous studies since their inaugural trial in 2018, they contribute valuable insights into this complex condition.
Further south in Kansas City at the University of Kansas Medical Center, researchers are conducting two active clinical trials aimed at deepening our understanding of dermatomyositis. Their commitment to researching this disease began in 2014 when they launched their initial trial. On the other side of the country, HMD Research LLC in Orlando has also recognized the importance of investigating dermatomyositis; despite being relatively new to clinical trials for this condition—having just started their first one in 2022—they currently have two active studies underway.
Lastly but certainly not least important is Austin Neuromuscular Center located right within Austin's vicinity where they too join forces by having initiated comprehensive investigations on dermatomysotis starting from year 2017; through these endeavors ,they continue undertaking two concurrent clinical tests along with four previously conducted ones as part an effort dedicated towards enhancing knowledge regarding such intricate ailment.
These hospitals' dedication to researching dermatomyositis showcases a collective commitment to finding answers and more effective treatment options for patients struggling with this challenging condition. By pushing boundaries through rigorous scientific exploration, we can hope for improved quality of life and brighter prospects ahead for individuals affected by dermatomyositis around the globe.
Which are the best cities for dermatomyositis clinical trials?
When it comes to dermatomyositis clinical trials, several cities emerge as top contenders for research and development. New York leads the pack with 16 active trials investigating treatments like Anti-Beta Interferon (PF-06823859), Nivolumab, and Cohort B interventions. Boston follows closely behind with 10 ongoing studies focusing on similar approaches such as Anti-Beta Interferon (PF-06823859) and Nivolumab. Saint Louis in Missouri and Kansas City in Kansas both offer eight active trials exploring therapies like PF-06823859 and Nivolumab. Philadelphia rounds out the list with seven ongoing trials examining various treatment options including Brepocitinib. These cities provide individuals battling dermatomyositis access to cutting-edge clinical trials that pave the way for advancements in care and hope for better outcomes.
Which are the top treatments for dermatomyositis being explored in clinical trials?
Exciting advancements are on the horizon for dermatomyositis treatment, with several promising options currently being explored in clinical trials. Leading the charge is PF-06823859, a cutting-edge drug that is actively being tested in one trial dedicated to addressing dermatomyositis. Joining its ranks is GLPG3667, another innovative treatment option undergoing evaluation in one active trial. Not to be overlooked is brepocitinib, an emerging therapy showing promise and making waves with its inclusion in a single ongoing dermatomyositis trial. Additionally, anti-Beta interferon (PF-06823859) has shown potential as it enters the scene with one active study underway. These groundbreaking treatments provide hope for patients battling dermatomyositis and may pave the way for improved outcomes and quality of life.
What are the most recent clinical trials for dermatomyositis?
Recent clinical trials offer hope for individuals with dermatomyositis, a challenging autoimmune disease that affects the skin and muscles. Pioneering studies include Phase 3 trials of PF-06823859, which have shown promising results in the treatment of dermatomyositis. Another Phase 2 trial investigated GLPG3667 as a potential therapeutic option for this condition. Additionally, an Open Label Extension (OLE) Period study focused on M5049 high dose demonstrated encouraging outcomes in patients with dermatomyositis during Phase 2 testing. Brepocitinib has also undergone Phase 3 trials and displayed positive effects in managing this complex disorder. Lastly, Anti-Beta Interferon (PF-06823859) showcased its potential benefits during a Phase 2 trial targeting dermatomyositis. These innovative clinical investigations bring new possibilities for better management and improved quality of life for those living with dermatomyositis.
What dermatomyositis clinical trials were recently completed?
Recently completed clinical trials in dermatomyositis have shown promising advancements in the search for effective treatments. In November 2020, Kezar Life Sciences successfully completed a trial investigating KZR-616 as a potential therapy for this challenging condition. Additionally, Corbus Pharmaceuticals Inc.'s trial testing Lenabasum 20 mg concluded in December 2018. Earlier progress was made with Pfizer's PF-06823859 low, completing its trial in January 2018. These studies highlight the ongoing efforts to find innovative solutions to alleviate the burden of dermatomyositis and improve patients' lives.